In recent years, exceptional technological advances have enabled the identification and
interrogation of rare circulating tumour cells (CTCs) from blood samples of patients, leading …

Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …

Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …

Cancer cells, including melanoma cells, often metastasize regionally through the lymphatic
system before metastasizing systemically through the blood,,–; however, the reason for this …

The state and behaviour of a cell can be influenced by both genetic and environmental
factors. In particular, tumour progression is determined by underlying genetic aberrations …

Based on engineered or bacterial nucleases, the development of genome editing
technologies has opened up the possibility of directly targeting and modifying genomic …

Small cell lung cancer (SCLC) is a neuroendocrine tumor treated clinically as a single
disease with poor outcomes. Distinct SCLC molecular subtypes have been defined based …

Small-cell lung cancer (SCLC) is a deadly tumour accounting for approximately 15% of lung
cancers and is pathologically, molecularly, biologically and clinically very different from other …

The translational challenges in the field of precision oncology are in part related to the
biological complexity and diversity of this disease. Technological advances in genomics …

Lymph node metastases in cancer patients are associated with tumor aggressiveness,
poorer prognoses, and the recommendation for systemic therapy. Whether cancer cells in …